Leucovorin Calcium: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Leucovorin Calcium appears in the FDA drug-label database. Marketed as LEUCOVORIN CALCIUM.
FDA-approved use
Leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent over dosages of folic acid antagonists. Leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form.
FDA recalls / enforcement
| Reason (FDA) | Classification | Status | Initiated |
|---|---|---|---|
| Failed Tablet/Capsule Specifications: Tablets are imprinted with the incorrect identification code. — West-Ward Columbus Inc | Class III (FDA: unlikely to cause harm) | Terminated | 2020-07-22 |
Phase breakdown
Conditions being studied
Recruiting trials involving Leucovorin Calcium
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
- FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
- Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Common questions
Is Leucovorin Calcium FDA-approved?
Yes, marketed as LEUCOVORIN CALCIUM.
How many recruiting trials involve Leucovorin Calcium?
4 recruiting trials across 14 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.